Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea

This study has been completed.
Sponsor:
Collaborator:
Nielsen, Jens OD, M.D.
Information provided by:
Viborg Hospital
ClinicalTrials.gov Identifier:
NCT00452855
First received: March 26, 2007
Last updated: March 28, 2007
Last verified: March 2007

March 26, 2007
March 28, 2007
January 2002
Not Provided
  • Nausea, incidence and intensity ( VAS score )in PACU and surgical ward
  • Vomiting, incidence in PACU and surgical ward
  • Total PONV after 24 hours
Same as current
Complete list of historical versions of study NCT00452855 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea
Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery

The purpose of this study is to determine whether sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia concerning post- operative nausea and vomiting.

Propofol and sevoflurane anaesthesia are used world wide at the anaesthetists discretion.

Propofol is superior to inhalational anaesthetics as anaesthesia for patients at risk of post operative nausea and vomiting (PONV) as PONV is diminished. However, when remifentanil is used as adjuvant to sevoflurane, the total dose of the latter is reduced.

Therefore, we wanted to investigate if sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia with emphasis on nausea, vomiting and total PONV during 24 hours.

In the post anaesthesia care unit (PACU) and in the surgical ward nausea was scored on a visual analogue score. Vomiting was registered.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • Nausea
  • Vomiting
Procedure: Sevoflurane-remifentanil anaesthesia
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
160
May 2005
Not Provided

Inclusion Criteria:

  • Females younger than 50 years
  • ASA I-II
  • Scheduled to gynaecological laparotomies or laparoscopies

Exclusion Criteria:

  • Medication known to act anti-emetic
  • ASA status greater than II
  • Malignant hyperthermia
  • Allergy to the drugs used.
Female
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00452855
PropSevoRemi
No
Not Provided
Viborg Hospital
Nielsen, Jens OD, M.D.
Principal Investigator: Jens Ole Dich JO Nielsen, MD
Viborg Hospital
March 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP